Los Angeles Capital Management LLC Purchases 21,101 Shares of Iovance Biotherapeutics, Inc. $IOVA

Los Angeles Capital Management LLC boosted its position in Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) by 127.5% during the second quarter, according to its most recent 13F filing with the SEC. The firm owned 37,655 shares of the biotechnology company’s stock after acquiring an additional 21,101 shares during the period. Los Angeles Capital Management LLC’s holdings in Iovance Biotherapeutics were worth $65,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Avantax Advisory Services Inc. increased its stake in shares of Iovance Biotherapeutics by 39.0% in the first quarter. Avantax Advisory Services Inc. now owns 18,560 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 5,205 shares in the last quarter. Grimes & Company Inc. boosted its holdings in Iovance Biotherapeutics by 17.6% in the 2nd quarter. Grimes & Company Inc. now owns 37,839 shares of the biotechnology company’s stock worth $65,000 after buying an additional 5,672 shares during the period. Accredited Investors Inc. purchased a new position in Iovance Biotherapeutics in the 1st quarter valued at approximately $33,000. WealthTrust Axiom LLC bought a new stake in Iovance Biotherapeutics during the 1st quarter valued at $33,000. Finally, Flputnam Investment Management Co. purchased a new stake in shares of Iovance Biotherapeutics during the first quarter worth $37,000. 77.03% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on IOVA shares. Chardan Capital reduced their price target on Iovance Biotherapeutics from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Thursday, November 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Iovance Biotherapeutics in a research note on Wednesday, October 8th. Wells Fargo & Company reduced their target price on Iovance Biotherapeutics from $18.00 to $14.00 and set an “overweight” rating for the company in a report on Friday, August 8th. Zacks Research raised shares of Iovance Biotherapeutics to a “hold” rating in a report on Tuesday, August 12th. Finally, HC Wainwright reduced their price objective on shares of Iovance Biotherapeutics from $20.00 to $9.00 and set a “buy” rating for the company in a research note on Wednesday, October 29th. Six investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, Iovance Biotherapeutics presently has a consensus rating of “Hold” and a consensus target price of $10.50.

Iovance Biotherapeutics Stock Up 0.8%

Shares of Iovance Biotherapeutics stock opened at $2.44 on Wednesday. Iovance Biotherapeutics, Inc. has a 12-month low of $1.64 and a 12-month high of $9.70. The firm has a market cap of $968.61 million, a PE ratio of -2.03 and a beta of 0.87. The company’s fifty day simple moving average is $2.21 and its two-hundred day simple moving average is $2.22.

Iovance Biotherapeutics (NASDAQ:IOVA) last issued its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Iovance Biotherapeutics had a negative return on equity of 55.24% and a negative net margin of 158.78%.The firm had revenue of $67.46 million for the quarter, compared to analyst estimates of $76.20 million. Iovance Biotherapeutics has set its FY 2025 guidance at EPS. As a group, sell-side analysts expect that Iovance Biotherapeutics, Inc. will post -1.24 earnings per share for the current fiscal year.

Iovance Biotherapeutics Company Profile

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.